Flash e-reader

 Go to e-reader chapter








PDF FormatRequires Adobe Acrobat Reader

Table 13.6a

Immunosuppression Use for Induction, 2000 to 2009

Recipients with Heart-Lung Transplants

  Year of Transplant
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Transplants 48 27 33 29 40 35 31 31 27 29
With Immunosuppression Info 48 26 33 28 38 33 30 29 22 27
Induction Drugs 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ALG
Atgam/NRATG/NRATS 29.2% 26.9% 15.2% 3.6% 13.2% 12.1% 3.3% 31.0% 13.6% 7.4%
OKT3 6.3% 0.0% 6.1% 3.6% 2.6% 3.0% 0.0% 6.9% 0.0% 0.0%
Thymoglobulin 4.2% 11.5% 3.0% 10.7% 13.2% 3.0% 6.7% 3.4% 0.0% 0.0%
Zenapax 12.5% 7.7% 15.2% 7.1% 18.4% 12.1% 16.7% 10.3% 40.9% 29.6%
Simulect 4.2% 30.8% 18.2% 17.9% 10.5% 24.2% 10.0% 24.1% 4.5% 14.8%
Campath 0.0% 0.0% 0.0% 0.0% 5.3% 9.1% 23.3% 17.2% 13.6% 3.7%
No Induction Drugs Recorded 47.9% 26.9% 42.4% 57.1% 42.1% 39.4% 40.0% 20.7% 27.3% 44.4%


Source: OPTN/SRTR Data as of October 1, 2010.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.

Individual induction drug percentages will not necessarily add up to 100 percent, as patients may be prescribed more than one induction drug.